PDF(Pubmed)
Abstract：
BACKGROUND: Prostate cancer is the leading cause of cancer-related death and the second most commonly diagnosed cancer among men in Uganda and most countries in Sub-Saharan Africa (SSA). The TMPRSS2-ERG fusion gene is the most common genetic alteration seen among prostate cancer patients. There are several contradicting reports about the association of ERG protein with poor prognosis, high PSA, and Gleason score. This study determined the prevalence of ERG expression and the relationship with PSA, Gleason score, and Age of prostate cancer patients in Southwestern Uganda.
METHODS: We reviewed 130 archived prostate biopsy (needle and TURP) specimens from patients of age ≥ 50 years who had a histological diagnosis of prostate cancer. We obtained their biodata, and preoperative PSA, from the archived records. We did Immunohistochemistry (IHC) to determine the prevalence of ERG expression.
RESULTS: The mean patient age in our study was 74.64 ± 10.19 years. Pre-operative PSA levels had been done for 79.2% of the participants. Most cancers (58.46%) were of high grade (grade group 3-5). ERG expression prevalence was 75.4% and its expression was independent of age, re-operative PSA, and Gleason score.
CONCLUSIONS: There is a significantly higher prevalence of ERG expression in our study compared to what is reported in other African-based studies. The expression of the ERG is independent of age, Gleason score, and serum PSA levels. A high proportion of our prostate cancer has high-grade disease at the time of diagnosis.
METHODS: We reviewed 130 archived prostate biopsy (needle and TURP) specimens from patients of age ≥ 50 years who had a histological diagnosis of prostate cancer. We obtained their biodata, and preoperative PSA, from the archived records. We did Immunohistochemistry (IHC) to determine the prevalence of ERG expression.
RESULTS: The mean patient age in our study was 74.64 ± 10.19 years. Pre-operative PSA levels had been done for 79.2% of the participants. Most cancers (58.46%) were of high grade (grade group 3-5). ERG expression prevalence was 75.4% and its expression was independent of age, re-operative PSA, and Gleason score.
CONCLUSIONS: There is a significantly higher prevalence of ERG expression in our study compared to what is reported in other African-based studies. The expression of the ERG is independent of age, Gleason score, and serum PSA levels. A high proportion of our prostate cancer has high-grade disease at the time of diagnosis.
摘要：
背景：前列腺癌是导致癌症相关死亡的主要原因，也是乌干达和撒哈拉以南非洲（SSA）大多数国家男性中第二常见的癌症。TMPRSS2-ERG融合基因是前列腺癌患者中最常见的遗传改变。关于ERG蛋白与不良预后的相关性，有一些相互矛盾的报道。高PSA,和格里森得分。这项研究确定了ERG表达的患病率以及与PSA的关系。格里森得分,乌干达西南部前列腺癌患者的年龄。
方法：我们回顾了130份来自年龄≥50岁、组织学诊断为前列腺癌的患者的前列腺活检（针吸和TURP）标本。我们得到了他们的生物数据,术前PSA,从存档记录中。我们进行了免疫组织化学（IHC）以确定ERG表达的患病率。
结果：我们研究的患者平均年龄为74.64±10.19岁。79.2%的参与者进行了术前PSA水平测定。大多数癌症（58.46％）为高级别（3-5级）。ERG表达患病率为75.4%，其表达与年龄无关，再次操作的PSA,和格里森得分。
结论：与其他基于非洲的研究相比，我们的研究中ERG表达的患病率明显更高。ERG的表达与年龄无关，格里森得分,和血清PSA水平。在诊断时，我们的前列腺癌中有很大一部分患有高级疾病。
方法：我们回顾了130份来自年龄≥50岁、组织学诊断为前列腺癌的患者的前列腺活检（针吸和TURP）标本。我们得到了他们的生物数据,术前PSA,从存档记录中。我们进行了免疫组织化学（IHC）以确定ERG表达的患病率。
结果：我们研究的患者平均年龄为74.64±10.19岁。79.2%的参与者进行了术前PSA水平测定。大多数癌症（58.46％）为高级别（3-5级）。ERG表达患病率为75.4%，其表达与年龄无关，再次操作的PSA,和格里森得分。
结论：与其他基于非洲的研究相比，我们的研究中ERG表达的患病率明显更高。ERG的表达与年龄无关，格里森得分,和血清PSA水平。在诊断时，我们的前列腺癌中有很大一部分患有高级疾病。
